Perioperative risk of bleeding with antithrombotic agents in macular surgery: a national, prospective, multicentre study
Authors:
- Pierre‐Henry GabriellePierre‐Henry Gabrielle
- Catherine Creuzot‐GarcherCCCatherine Creuzot‐Garcher
- for the CFCR Research netFNfor the CFCR Research net
- 12 April 2020
- journal article
- research article
- Published by Wiley in Acta Ophthalmologica
- Vol. 98 (8) , E991-E997
Abstract
Purpose: To compare the risk of haemorrhagic complications in elective macular surgery between patients with no antithrombotic (AT) treatment (defined as patients with no history of AT therapy or who discontinued AT therapy) and patients who continued AT treatment during the surgery.Methods: E‐case report forms were prospectively recorded in a database before vitreoretinal surgery and 1 month after. Data on patient characteristics, surgical techniques, haemorrhagic complications and antithrombotic status were collected. Patients with retinal detachment, proliferative diabetic retinopathy and previous retinal haemorrhage were excluded.Results: A total of 748 procedures (single procedure in one eye per patient) were performed between January and May 2019. Among them, 202 patients (27.0%) were treated with antithrombotic therapy at the time of surgery: 19.5% with antiplatelet agents (n = 146), 6.3% with anticoagulants (n = 47) including 3.2% (n = 24) patients treated with novel oral anticoagulants, 0.8% (n = 6) with anticoagulants and antiplatelet agents, and 0.4% (n = 3) with heparin. Overall, 92 patients (12.3%) developed one or more haemorrhagic complications, of which 63 (11.5%) and 29 (14.4%) were in the non‐AT and AT group, respectively. The multivariate logistic regression model showed no difference between AT treatment groups regarding ocular bleeding complications (odds ratio [OR] 1.2, 95% confidence interval (CI) [0.7–2.2], p = 0.54).Conclusion: No cases of uncontrolled or severe perioperative haemorrhage in patients continuing antithrombotic agents were reported in this selected population. For the majority of the patients taking antiplatelets or anticoagulants, these agents could be safely continued during macular surgery.Keywords
Funding Information
- CFSR Recherche
This publication has 27 references indexed in Scilit:
- Management of peri‐operative anti‐thrombotic therapyAnaesthesia, 2014
- Ophthalmic patients on antithrombotic drugs: a review and guide to perioperative managementBritish Journal of Ophthalmology, 2014
- New oral anticoagulants and oculoplastic surgeryCanadian Journal of Ophthalmology, 2014
- Risk of Major Adverse Cardiac Events Following Noncardiac Surgery in Patients With Coronary StentsJAMA, 2013
- Forecasting the Impact of Heart Failure in the United StatesCirculation: Heart Failure, 2013
- Maintenance of perioperative antiplatelet and anticoagulant therapy for vitreoretinal surgeryClinical & Experimental Ophthalmology, 2012
- MAINTENANCE OF ANTICOAGULANT AND ANTIPLATELET AGENTS FOR PATIENTS UNDERGOING PERIBULBAR ANESTHESIA AND VITREORETINAL SURGERYRetina, 2012
- Peribulbar block in patients scheduled for eye procedures and treated with clopidogrelJournal of Anesthesia, 2012
- Antiplatelet and Anticoagulation Therapy in Vitreoretinal SurgeryAmerican Journal of Ophthalmology, 2011
- Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgeryOphthalmology, 2003